Proteomics International’s Promarker™ Platform for protein biomarker discovery is a multi-step process. Grey lines indicate project progress as reported in The Company’s 2020 Annual Report.
Biomarker discovery, verification and analytical validation is available as a fee for service model, or through a collaborative partnership with Proteomics International. Read more.
The Promarker™ Platform is currently being used to investigate the protein ‘fingerprints’ associated with the following diseases of unmet need:
Diabetic Kidney Disease
Status update: Commercialised
Three biomarkers for Diabetic Kidney Disease identified by the Promarker™ Platform have been verified, validated, and developed into a commercially available test: PromarkerD.
Status update: Agreements to access samples for Clinical Validation study finalised; Clinical Validation study pending
Proteomics International has identified and filed a patent application describing a panel of novel protein biomarkers with the potential to be developed into a simple blood test for endometriosis (See Window on the Science 2021). Given the large unmet medical need and the deficiencies in existing diagnostic tools, Proteomics International believes there will be significant commercial interest in this program post successful clinical study validation.
Over the past year Proteomics International has been testing the stability of the discovered biomarker panel as part of the Proof of Concept. This ensures the quality and analytical reproducibility of the biomarker panel before moving into the current Clinical Study phase of the project.
Subsequent to the year end, Proteomics International signed a research collaboration agreement with the University of Melbourne and the Royal Women’s Hospital (the Women’s), enabling access to the Women’s world-leading endometriosis database containing anonymous biological samples and survey information. The collaboration will seek to validate the panel of biomarkers discovered by Proteomics International, and also to identify new biomarkers for the disease.
Giardia (causing gastroenteritis)
Status update: Results from Validation study under analysis.
Proteomics International continues its development of an improved diagnostic test for the parasite Giardia in collaboration with the Murdoch University Veterinary School and a leading US veterinary company. Giardia is a leading cause of infectious gastroenteritis worldwide and one of the most common parasitic human diseases. Proteomics International has identified strain specific Giardia targets and developed a prototype immunoassay, which is pending validation using field samples. This aspect was delayed by the COVID-19 pandemic and analysis of the data from the field samples remains ongoing.
Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Status update: Results from Proof-of-Concept study under analysis.
Proteomics International is working to identify biomarkers for asthma and chronic obstructive pulmonary disease, which cost healthcare systems tens of billions of dollars a year. The study is in collaboration with the Busselton Population Medical Research Institute, which gives Proteomics International access to the globally-recognised Busselton Health Study, first established in 1966 and one of the longest running epidemiological research programs in the world.
Plant Dieback (Phytophthora cinnamomi)
Status update: Results from Discovery study under analysis.
Proteomics International has an ongoing collaboration with the Centre for Crop and Disease Management (Curtin University) to target the plant pathogen Phytophthora cinnamomi, which is responsible for plant dieback that affects a wide variety of native plant species and premium crops such as avocados and macadamias.
The estimated cost to the Australian economy is $160 million per year for damage to natural vegetation alone. Current investigations are focused on proteomic analysis (determining the protein maps) of the life stages of the organism and how it infects its host. This may lead to a field test for the easier detection of infected soil, and has the potential to identify weaknesses in the pathogen that could be targeted to help eradicate this disease.
Status update: Results from Discovery study under analysis.
Following the success of its diabetic kidney disease project, Proteomics International extended its collaboration agreement with The University of Western Australia to seek early markers for diabetic retinopathy, the major cause of blindness in the US. This collaboration is applying the Promarker™ platform to look for prognostic markers in the blood that can identify patients at risk of retinopathy, especially sight-threatening retinopathy. The program is again utilising the Fremantle Diabetes Study which provided the rich sample repository that led to PromarkerD.
Oxidative stress (2-tag)
Status update: Validation studies pending; Commercialisation discussions underway
Proteomics International has been in a long-term collaboration with The University of Western Australia to develop methodology that could become the next generation of medical diagnostic tests. The patented technology called “2-tag” measures the oxidative stress in a system. Proteomics International holds a number of patents covering the “2-tag” method and is currently in commercial negotiations to unlock value from this innovative technology.
Every person has a base level of oxidative stress at all times – the human body requires oxidative stress to function. However, very high levels of oxidative stress can be dangerous and have been linked to a wide range of chronic diseases including stroke, heart attack, Parkinson’s disease, and muscular dystrophy and muscle damage.
The technology has now matured with the 2-tag test demonstrating proof of concept with several publications targeting Duchenne muscular dystrophy and new exploratory work in aquaculture and sports management. Proteomics International is currently examining commercial opportunities with The University of Western Australia to exploit this innovative technology.
Status update: Technology transfer ongoing; Clinical Validation pending.
Proteomics International has joined forces with QIMR Berghofer Medical Research Institute to improve detection of oesophageal adenocarcinoma, the most common form of oesophageal cancer in Australia. Proteomics International is employing its Promarker™ platform to analytically and then clinically validate a panel of biomarkers – protein ‘fingerprints’ in the blood – that QIMR Berghofer researchers found are associated with early stages of the cancer. The aim is to develop a simple blood test for oesophageal adenocarcinoma.
Retinopathy – ARC Centre for Personalised Therapeutics Technologies
Status update: Discovery study ongoing.
Proteomics International is collaborating with the Lions Eye Institute and The University of Western Australia as part of the Australian Research Council Centre for Personalised Therapeutics Technologies, a $3.1 million Federally funded Industrial Transformation Training Centre (ITTC). Proteomics International is working alongside leading university-based researchers to apply the Promarker™ technology to seek a Complementary Diagnostic test to assess treatments for eye disease.
Status update: Development study completed, project suspended.
In 2020, Proteomics International was awarded two grants under the Western Australian COVID-19 Research Grants Program to support research into COVID-19 biomarkers and diagnostics. The development studies were completed, however, the research programs have been suspended in light of the extensive resources directed at COVID-19 worldwide.